Allergan Receives 2016 ENERGY STAR Partner Of The Year Award From U.S. EPA

DUBLIN, March 30, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an ENERGY STAR 2016 Partner of the Year Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors.

Logo -

Allergan has been an ENERGY STAR partner since 1996 and recognized by the EPA for the fifth time. The 2016 Partner of the Year Sustained Excellence Awards are presented to organizations recognizing their contributions to reducing harmful carbon pollution through superior energy efficiency efforts. These awards recognize ongoing leadership in the ENERGY STAR program.

"By continued collaboration with ENERGY STAR, Allergan is helping Americans save money, save energy, and do their part to reduce our nation's greenhouse gas emissions that exacerbate climate change," said EPA Administrator Gina McCarthy. "I'm proud to recognize Allergan with the highest form of ENERGY STAR recognition, as the winner of the 2016 Partner of the Year Sustained Excellence Award. Allergan demonstrates a strong commitment to energy efficiency and to preserving a healthy planet for future generations."

The award also recognizes four Allergan manufacturing sites that have achieved ENERGY STAR rankings in the top 25 percent of pharmaceutical plant energy performance nationwide: Waco, Texas for eight consecutive years, and first time awards for Cincinnati, Ohio; Fajardo, Puerto Rico; and Manati, Puerto Rico. Also achieving ENERGY STAR certification this year were five buildings at the Allergan campus in Irvine, CA.

"Allergan has a long history and commitment to improving our energy performance and reducing our impact on the environment, and we are proud to be recognized by ENERGY STAR for our efforts," said Wayne Swanton, Senior Vice President, Global Operations at Allergan. "Our partnership with ENERGY STAR is part of our ongoing commitment to the environment, including using greener sources of energy and reducing greenhouse gas emissions within our operations."

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at


ENERGY STAR® is the simple choice for energy efficiency. For more than 20 years, people across America have looked to EPA's ENERGY STAR program for guidance on how to save energy, save money, and protect the environment. Behind each blue label is a product, building, or home that is independently certified to use less energy and cause fewer of the emissions that contribute to climate change. Today, ENERGY STAR is the most widely recognized symbol for energy efficiency in the world, helping families and businesses save $362 billion on utility bills, while reducing greenhouse gas emissions by more than 2.4 billion metric tons since 1992. Join the millions who are already making a difference at

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


Lisa DeFrancesco 
(862) 261-7152

Mark Marmur 
(862) 261-7558


To view the original version on PR Newswire, visit:

SOURCE Allergan plc

Back to news